Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Trasveda Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct art unit and involves 1 distinct examiner. The company's patent prosecution profile is currently very focused on this one interaction, which represents their entire active presence at the patent office.
JOHNSON, CHRISTOPHER LINDSAY is the busiest examiner, with the 1 pending office action. Because the entire active portfolio consists of this one action, the practitioner's focus should be entirely on the specific requirements and feedback from this examiner. The concentration in 1 art unit and with 1 examiner simplifies the management of the portfolio but makes the outcome of this one case highly significant for the company's standing in the Biotechnology & Pharmaceuticals sector.
With only 1 pending office action, the company does not need to manage complex examiner relationships or diverse art unit standards. For a practitioner, this allows for a bespoke prosecution strategy tailored specifically to JOHNSON, CHRISTOPHER LINDSAY. The success of this single application is the primary metric for the company's current patent efforts, requiring a high level of precision in every communication with the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 46.9% | +81.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19539493 | Compounds with Anti-KRAS Mutated Tumor Activity | JOHNSON, CHRISTOPHER LINDSAY | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19539493 | Compounds with Anti-KRAS Mutated Tumor Activity | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §112DP | Non-Final OA | — | Pending | Feb 13, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial